India, Oct. 15 -- Physiotherapist Lakshya Bhaktyani of PSRI Hospital and Kushal Pal Singh, fitness and performance expert at Anytime Fitness India, have outlined how Garba during Navratri can function... Read More
India, Oct. 15 -- Paediatrician Dr Rajiv Chhabra of Artemis Hospital, Gurugram, shared five everyday changes parents can make at home to reduce preventable health risks for children, according to an H... Read More
India, Oct. 15 -- Hindustan Times Lifestyle reported on guidance shared by wellness and nutrition expert Dr Namita Jain on Oct. 2, 2026, and by ophthalmologist Dr Rishi Bhardwaj on Oct. 15, 2026, alon... Read More
India, Oct. 15 -- Surgical oncologist Dr Naveen Sanchety and ophthalmologist Dr Rishi Bhardwaj, speaking to HT Lifestyle in separate articles updated and published on Oct. 14 and Oct. 15, 2026, descri... Read More
Singapore, Oct. 15 -- The Health Sciences Authority received information related to the study titled 'A Phase 1, Randomized, Placebo-Controlled, Single and Multiple Ascending Dose-Escalation Study to ... Read More
Singapore, Oct. 15 -- The Health Sciences Authority received information related to the study titled 'A Phase 2 Platform Basket Study Evaluating Advanced Therapies in Subjects with Moderately to Sever... Read More
Singapore, Oct. 15 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Randomized, Open-Label Study of Rinzimetostat (ORIC-944) in Combination with Darolutami... Read More
Singapore, Oct. 15 -- The Health Sciences Authority received information related to the study titled 'An Interventional Phase 3, Open Label, Randomized Study To Evaluate Efficacy And Safety of PF-0863... Read More
Singapore, Oct. 15 -- The Health Sciences Authority received information related to the study titled 'A Randomized, Double-blind, Phase 3 Study of Pembrolizumab + Pemetrexed + Platinum Chemotherapy Wi... Read More
Singapore, Oct. 15 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Randomized, Open-Label Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Ver... Read More